All
Nudes and Breast Cancer: Personal Documentary and Art
June 13th 2018Sometimes breast cancer invites us to look closely at our own bodies the way we might look at famous nudes. Creating visual art can be therapeutic, whether it involves photography or digital. Watercolors, sketches and collages could be empowering, too.
Survey Sheds Light on Why Some Use Cannabis After Stem Cell Transplant
June 13th 2018Nearly 20 percent of hematopoietic stem cell transplant (HSCT) survivors reported using cannabis, not just to ease physical and emotional side effects, but in the hopes that it would help treat their cancer, according to patient survey results presented at the 2018 of American Society of Clinical Oncology (ASCO) Annual Meeting.
FDA Grants Priority Review to GARDASIL 9 for Expanded Age Indication
June 13th 2018The application is seeking approval for GARDASIL 9 to be used in women and men aged 27 to 45 years for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine.
FDA Approves Addition of Survival Data to Kyprolis Label for Multiple Myeloma Treatment
June 12th 2018The Food and Drug Administration (FDA) approved the supplemental New Drug Application to add to the U.S. Prescribing Information for Kyprolis (carfilzomib) for the treatment of patients with relapsed or refractory multiple myeloma.
Specialized Care Is Needed for Adolescent and Young Adult Cancer Survivors
June 11th 2018The survey contained questions on a range of issues they may have experienced, including pain, fatigue, as well as issues with sexual function, body image and finances. Researchers then looked at the anxiety and depression associated with those issues, and talked with patients about what they thought might be causing those problems.
Patients With Myeloma Precursor Report Worse Quality of Life
June 8th 2018Cancer affects many aspects of a person’s life, such as the overall quality of their day-to-day living, but what if a person didn’t have the full-blown disease already? Could a precursor or asymptomatic stage of the disease still burden them?
Venclexta Combination Receives Full FDA Approval for CLL, With or Without 17p deletion
June 8th 2018The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.